Key points are not available for this paper at this time.
Highlights| March 01 2024 Selected Articles from This Issue Author 30 (5): 929. https://doi.org/10.1158/1078-0432.CCR-30-5-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Addition of anti-PD-1 and PD-L1 immunotherapies to chemotherapy and radiation for the treatment of cervical cancer has had mixed clinical results. As TGF-β has been shown to promote tumor progression and immune escape in human papillomavirus (HPV)-associated cervical cancer, it has been suggested that targeting both the immunosuppressive TGF-β and PD-L1 pathways may improve patient outcomes. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of a TGF-β "trap" fused to a PD-L1 monoclonal antibody. In this phase Ib trial, Oaknin and colleagues evaluate the combination of bintrafusp alfa with cisplatin or carboplatin plus paclitaxel or radiation, with or without the VEGF-A monoclonal antibody bevacizumab in patients with locally advanced or persistent, recurrent, or metastatic (P/R/M) cervical cancer. The combination therapies were tolerable, with most adverse events being grade 1-2. The authors report promising activity, with an objective response rate of 75.0% in patients receiving bintrafusp alfa, cisplatin or carboplatin,... You do not currently have access to this content.
A Fri, study studied this question.